Targeting the CD22 receptor on human B-cell lymphomas with RNA damaging agents.

被引：0
|
作者：
Newton, DL
Mikulski, SM
Sausville, EA
Rybak, SM
机构：
[1] NCI, Frederick Canc Res & Dev Ctr, DCTD, DTP, Frederick, MD 21702 USA
[2] Alfacell Corp, Bloomfield, NJ 07003 USA
来源：
CLINICAL CANCER RESEARCH | 2000年 / 6卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
469
引用
收藏
页码：4560S / 4560S
页数：1
相关论文
共 50 条
  • [31] DEVELOPMENT OF HUMAN B-CELL LINES DEFICIENT IN CD19, CD20, OR CD22
    WILSON, GL
    RIVA, A
    KEHRL, JH
    JOURNAL OF IMMUNOLOGY, 1993, 150 (08): : A99 - A99
  • [32] EVALUATION OF 4 CD22 ANTIBODIES AS RICIN A CHAIN-CONTAINING IMMUNOTOXINS FOR THE INVIVO THERAPY OF HUMAN B-CELL LEUKEMIAS AND LYMPHOMAS
    SHEN, GL
    LI, JL
    GHETIE, MA
    GHETIE, V
    MAY, RD
    TILL, M
    BROWN, AN
    RELF, M
    KNOWLES, P
    UHR, JW
    JANOSSY, G
    AMLOT, P
    VITETTA, ES
    THORPE, PE
    INTERNATIONAL JOURNAL OF CANCER, 1988, 42 (05) : 792 - 797
  • [33] THE B-CELL ANTIGEN CD22 MEDIATES MONOCYTE AND ERYTHROCYTE ADHESION
    STAMENKOVIC, I
    SEED, B
    NATURE, 1990, 345 (6270) : 74 - 77
  • [34] Sequential CD22 Targeting Impacts CD22 CAR-T Cell Response
    Yates, Bonnie
    Shalabi, Haneen
    Salem, Dalia
    Delbrook, Cynthia
    Yuan, Constance M.
    Stetler-Stevenson, Maryalice
    Fry, Terry J.
    Shah, Nirali N.
    BLOOD, 2018, 132
  • [35] Targeting CD22 with the monoclonal antibody epratuzumab modulates human B-cell maturation and cytokine production in response to Toll-like receptor 7 (TLR7) and B-cell receptor (BCR) signaling
    Natalia V. Giltiay
    Geraldine L. Shu
    Anthony Shock
    Edward A. Clark
    Arthritis Research & Therapy, 19
  • [36] Targeting CD22 with the monoclonal antibody epratuzumab modulates human B-cell maturation and cytokine production in response to Toll-like receptor 7 (TLR7) and B-cell receptor (BCR) signaling
    Giltiay, Natalia V.
    Shu, Geraldine L.
    Shock, Anthony
    Clark, Edward A.
    ARTHRITIS RESEARCH & THERAPY, 2017, 19
  • [37] Disubstituted sialic acid ligands targeting siglecs CD33 and CD22 associated with myeloid leukaemias and B cell lymphomas
    Rillahan, Cory D.
    Macauley, Matthew S.
    Schwartz, Erik
    He, Yuan
    McBride, Ryan
    Arlian, Britni M.
    Rangarajan, Janani
    Fokin, Valery V.
    Paulson, James C.
    CHEMICAL SCIENCE, 2014, 5 (06) : 2398 - 2406
  • [38] The B-cell inhibitory receptor CD22 is a major factor in host resistance to Streptococcus pneumoniae infection
    Fernandes, Vitor E.
    Ercoli, Giuseppe
    Benard, Alan
    Brandl, Carolin
    Fahnenstiel, Hannah
    Mueller-Winkler, Jennifer
    Weber, Georg F.
    Denny, Paul
    Nitschke, Lars
    Andrew, Peter W.
    PLOS PATHOGENS, 2020, 16 (04)
  • [39] In vivo targeting of B-cell lymphoma with glycan ligands of CD22 (vol 115, pg 4778, 2010)
    Chen, W. C.
    Completo, G. C.
    Sigal, D. S.
    BLOOD, 2011, 117 (20) : 5551 - 5551
  • [40] CD22 ASSOCIATES WITH THE HUMAN SURFACE IGM-B-CELL ANTIGEN RECEPTOR COMPLEX
    LEPRINCE, C
    DRAVES, KE
    GEAHLEN, RL
    LEDBETTER, JA
    CLARK, EA
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (08) : 3236 - 3240
12345